NCCN Guidelines® Insights: Cancer-associated venous thromboembolic disease, version 2.2018: Featured updates to the NCCN Guidelines Journal Article


Authors: Streiff, M. B.; Holmstrom, B.; Angelini, D.; Ashrani, A.; Bockenstedt, P. L.; Chesney, C.; Fanikos, J.; Fenninger, R. B.; Fogerty, A. E.; Gao, S.; Goldhaber, S. Z.; Gundabolu, K.; Hendrie, P.; Lee, A. I.; Lee, J. T.; Mann, J.; McMahon, B.; Millenson, M. M.; Morton, C.; Ortel, T. L.; Ozair, S.; Paschal, R.; Shattil, S.; Siddiqi, T.; Smock, K. J.; Soff, G.; Wang, T. F.; Williams, E.; Zakarija, A.; Hammond, L.; Dwyer, M. A.; Engh, A. M.
Article Title: NCCN Guidelines® Insights: Cancer-associated venous thromboembolic disease, version 2.2018: Featured updates to the NCCN Guidelines
Abstract: Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE. Copyright © 2018 by the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 11
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-11-01
Start Page: 1289
End Page: 1303
Language: English
DOI: 10.6004/jnccn.2018.0084
PUBMED: 30442731
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Gerald A Soff
    57 Soff